Current insights into the regulation of programmed cell death by TP53 mutation in cancer

Area of Science:

• Oncology
• Molecular Biology
• Cell Death Research

Background:

• Gene mutations, particularly in the TP53 gene, are critical in cancer initiation and progression.
• Programmed cell death encompasses various forms including apoptosis, pyroptosis, ferroptosis, and cuprotosis, crucial for maintaining homeostasis.
• Cancer cells evade programmed cell death, a key hallmark driving tumorigenesis.

Purpose of the Study:

• To review the intricate mechanisms by which TP53 mutations influence diverse programmed cell death pathways.
• To explore the interactions between different cell death modalities affected by TP53 mutations.
• To discuss clinical implications and potential targeted therapies for TP53-mutated cancers.

Main Methods:

• Literature review focusing on TP53 gene mutations and their effects on programmed cell death.
• Analysis of studies investigating the interplay between various cell death pathways (apoptosis, ferroptosis, etc.) and p53 status.
• Examination of clinical data and research on pharmacological interventions for TP53-mutated cancers.

Main Results:

• TP53 mutations disrupt multiple programmed cell death pathways, affecting cancer cell fate.
• Mutant p53 differentially impacts cell death, promoting ferroptosis while inhibiting apoptosis and autophagy.
• Interactions among cell death pathways are modulated by TP53 mutations, collectively influencing cancer progression.

Conclusions:

• TP53 mutations significantly alter programmed cell death, contributing to cancer development.
• Targeting these altered cell death pathways presents a promising avenue for novel cancer therapies.
• Further clinical investigation is warranted to develop effective treatments for TP53-mutated cancers.